Home/Pipeline/Sanoosa‑002

Sanoosa‑002

Solid Tumor Oncology

PreclinicalActive

Key Facts

Indication
Solid Tumor Oncology
Phase
Preclinical
Status
Active
Company

About Sanoosa

Australian biotech developing oral small‑molecule drugs for inflammation, oncology and viral infections.

View full company profile

Other Solid Tumor Oncology Drugs

DrugCompanyPhase
CIK Cell ImmunotherapyCytopeuticsPhase 1
TJC0434TaiwanJ PharmaceuticalsPreclinical